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Background: The pathological features of the common neurodegenerative conditions, Alzheimer’s disease (AD),
Parkinson’s disease and multiple sclerosis are all known to be associated with iron dysregulation in regions of the
brain where the specific pathology is most highly expressed. Iron accumulates in cortical plaques and neurofibrillary
tangles in AD where it participates in redox cycling and causes oxidative damage to neurons. To understand these
abnormalities in the distribution of iron the expression of proteins that maintain systemic iron balance was
investigated in human AD brains and in the APP-transgenic (APP-tg) mouse.
Results: Protein levels of hepcidin, the iron-homeostatic peptide, and ferroportin, the iron exporter, were
significantly reduced in hippocampal lysates from AD brains. By histochemistry, hepcidin and ferroportin were
widely distributed in the normal human brain and co-localised in neurons and astrocytes suggesting a role in
regulating iron release. In AD brains, hepcidin expression was reduced and restricted to the neuropil, blood vessels
and damaged neurons. In the APP-tg mouse immunoreactivity for ferritin light-chain, the iron storage isoform, was
initially distributed throughout the brain and as the disease progressed accumulated in the core of amyloid
plaques. In human and mouse tissues, extensive AD pathology with amyloid plaques and severe vascular damage
with loss of pericytes and endothelial disruption was seen. In AD brains, hepcidin and ferroportin were associated
with haem-positive granular deposits in the region of damaged blood vessels.
Conclusion: Our results suggest that the reduction in ferroportin levels are likely associated with cerebral
ischaemia, inflammation, the loss of neurons due to the well-characterised protein misfolding, senile plaque
formation and possibly the ageing process itself. The reasons for the reduction in hepcidin levels are less clear but
future investigation could examine circulating levels of the peptide in AD and a possible reduction in the passage
of hepcidin across damaged vascular endothelium. Imbalance in the levels and distribution of ferritin light-chain
further indicate a failure to utilize and release iron by damaged and degenerating neurons.
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Alzheimer’s disease (AD) is characterized by cerebrovas-
cular and neuronal dysfunction leading to a progressive
decline in cognitive functions and the development of
dementia [1-3]. Pathological hallmarks of AD include
neurofibrillary tangles consisting of hyper-phosphorylated
microtubule-associated protein tau [4,5] and extracellular
amyloid plaques derived from amyloid precursor protein
(APP), a widely expressed trans-membrane metalloprotein
essential for neuronal growth, survival, post-injury and
repair [6]. The main component of plaques is amyloid β
(Aβ) peptide, (38–43 amino acids) generated by sequential
cleavage of APP by β- and γ-secretase [7-10]. Recently, it
has been shown that oligomeric Aβ species (the smallest
of which are dimers) isolated from AD brains are the most
synaptotoxic forms found in amyloid plaques [11]. An-
other key protein involved in AD is apolipoprotein E
(ApoE), a major genetic risk factor with 60-80% of affected
individuals having at least one ApoE4 allele [12-15]. The
majority of plasma ApoE is produced by hepatocytes, cre-
ating a hepatic pool that is important for lipid metabolism,
while the second most common site of synthesis is the
brain [16,17]. ApoE is an Aβ chaperone, promoting its
transport across the blood brain barrier (BBB), a process
that is known to be impaired in AD [18-20].
Iron homeostasis in the mammalian brain is import-
ant, yet poorly understood. Excess iron in the form of
ferritin has been described in many neurodegenerative
disorders including AD and furthermore there is an ap-
parent link between an age-associated increase in iron
stores in the brain and the increasing incidence of AD
with advancing age [21-25]. Aβ and ferritin have been
shown to co-localise in the vascular amyloid deposits of
plaques in post-mortem AD brains [26,27] while iron ac-
cumulation in AD has been found to be a ready source
of redox generated free radicals that promote neuronal
cell death [28,29].
An increased understanding of how iron homeostasis
is maintained at the whole body and cellular levels has
followed from the identification of a number of iron
related proteins [30-34]. Hepcidin is a regulatory hor-
mone playing a key role in whole body iron homeostasis
[30]. This liver-derived peptide regulates systemic iron
homeostasis by controlling iron flux into the plasma
from the duodenum as well as iron recycling macro-
phages through binding to its receptor, the iron exporter
ferroportin [35-39]. Low serum hepcidin levels cause
iron overload, as in haemochromatosis, while increased
serum hepcidin expression plays an important role in
the anaemia of inflammation by restricting intestinal
iron absorption and macrophage iron release [40].
Hepcidin expression is modulated by systemic stimuli
such as iron stores, hypoxia, oxidative stress and inflam-
mation [31,41]. Ferroportin (FPN) is a transmembraneprotein, (also known as SLC40A1, IREG1, MTP1) that
exports iron from cells to plasma [42-44]. It is found on
the surface of macrophages, Kupffer cells, hepatocytes,
intestinal enterocytes and placental cells [32,45]. It is also
localized in the brain in most cell types including neuronal
perikarya, axons, dendrites and synaptic vesicles [46-49].
Recently, Duce and colleagues have reported that APP
may bind to ferroportin to facilitate neuronal iron export
and that disturbances in these processes may be impli-
cated in AD brain pathology [50].
The aim of our study was to explore a possible role for
these recently described proteins in the abnormalities of
iron metabolism previously described in the brain in
AD. Hepcidin and ferroportin proteins levels were
assessed by Western blotting in AD brains as compared
to age-matched controls. Cellular expression was investi-
gated by immunohistochemistry of brain sections and
comparisons were made with the distribution of AD
markers Aβ and ApoE.
In conjunction with exploring the progressive ab-
normalities in iron homeostasis in AD, we also in-
vestigated age-associated changes in the expression of
iron-handling proteins in the well-characterised APP
transgenic (APP-tg) mouse (APP/PS1-tg2576) model
[51-54]. We describe extensive blood vessel damage in
AD brain and a reduction in hepcidin and ferroportin
levels. In the APP-tg mouse model although the over-
all levels of ferritin in the brain were not increased
there may have been a re-distribution of iron as an in-




Synthetic hepcidin and ferroportin peptides were purchased
from Abcam, Cambridge. 4′,6-Diamidino-2′ phenylindole
dihydrochloride (DAPI), 3,3′-diaminobenzidine (DAB)
and methanol were from Sigma. Precast 4-12% NuPAGE
BisTris minigel and prestained protein molecular weight
markers were from Life technologies. Polyvinylidene
difluoride (PVDF) membrane, Western blotting detection
reagents (ECL Plus chemiluminescence reagents and
Hyperfilm) were from GE Healthcare (UK). Vectastain
ABC kit was from Vector laboratories (USA). Protease
and phosphatase inhibitors were from Roche laboratories
(Germany). BCA™ protein assay kit was from Thermo
Scientific (USA).
Sources of antibodies
The following primary antibodies were used: polyclonal
anti-hepcidin, polyclonal SLC40A1, mouse monoclonal
(MAB) anti-SLC40A1 (ferroportin), MAB anti-NG2,
MAB anti-ApoE E6D7, Polyclonal anti-apoE, MAB anti-
CD31, JC70A, Polyclonal anti-CD31, rabbit monoclonal
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The monoclonal anti-aβ antibody (6E10) (Covance,
Princeton, USA), rabbit anti-aβ (1-40) (Millipore) and
MAB anti-GFAP (Sigma). The following secondary
antibodies were used: biotinylated goat anti-rabbit
and biotinylated horse anti-mouse (both from Vector
Laboratories, 1:250 for IHC); Alexa Fluor 568-labelled
donkey anti-mouse, Alexa Fluor 488-labelled donkey
anti-rabbit, and Alexa Fluor 568-labelled donkey anti-
goat (all from Invitrogen, 1:1000 for IF). The dilutions
of each antibody stock are given in Table 1.
Human brain tissues
Human brain tissues from AD and age matched controls
were provided by the UK Brain Bank and permission
given by University of Cambridge, ethics committee for
use of these tissues (Table 2). Autopsy tissue was exam-
ined from 6 adults (age 74.0 ± 8.1 years) with
Alzheimer’s disease, meeting AD disease criteria (which
include dementia, episodic memory loss). Comparison
was made with six age-matched controls (age 82.0 ± 5.1
years) with no history of neurodegenerative diseases
[55]. Due to limitations of tissue availability from someTable 1 List of the primary antibodies used in this study
Antibody Species
Anti-β amyloid 1-16 amino acid (6E10) Mouse (monoclonal)
Anti-Hepcidin Rabbit (polyclonal)
Anti-Ferroportin (SLC40A1) Mouse (monoclonal)






Anti β-actin Mouse (monoclonal)
Anti-APOE Mouse (monoclonal)
Anti-APOE Rabbit (polyclonal)
Anti-Ferritin heavy chain Rabbit (polyclonal)
Anti-Ferritin light chain Rabbit (polyclonal)
Anti-Ferritin light-chain Mouse (monoclonal)
Anti-Myelin basic protein Mouse (monoclonal)
Anti-CD31 (JC/70A) Mouse (monoclonal)
Anti-CD31 Rabbit (monoclonal)
Anti-PDGFβR1 Mouse (monoclonal)
IHC, immunohistochemistry; WB, Western blotting.cases, it was not possible to include every case in all the
analyses (below). Numbers included in the different ana-
lyses thus vary as indicated.
Transgenic mice
APP-tg mice (Tg2576) over-expressing two human muta-
tions (K670N and V717F) and one PS1 mutation (M146V),
driven by Thy1 promoter were purchased from Jackson
Laboratory, USA.
All animals were housed under standard conditions
(12 h light-dark cycle, 20˚C ambient temperature) with
free access to food and water. All procedures were
performed under licence in accordance to the UK Animals
(Scientific Procedures) Act 1986.
Neuropathological characterisation of these animals
has previously been described in detail [51,52]. By 4-6
months of age, extensive amyloid plaque deposition is
seen in hippocampus and cortical regions. Six mice from
each age group (2, 4, 6, and 10 months-old) were used
for immunohistochemistry and as described subse-
quently, six for protein quantitation by Western blotting.
C57/bl mice were (n=6, age-matched to APP-tg mice)
were used as control samples.Dilution Supplier/cat. number
1: 1000 for IHC Covance cat number (SIG 39320)
1:2000 for WB
1: 200 for IHC Abcam (Ab30760) (0.9 mg/ml)
1:100 for WB
1: 1000 for IHC Abcam (ab93438) (1 mg/ml)
1:200 for IHC Abcam (ab85370) (1 mg/ml)
1:500 for IHC Abcam (ab83508) (0.5 mg/ml)
1:500 for IHC Abcam (ab83178) (0.4 mg/ml)
1:1000 for IHC Sigma (G3893 Clone G-A-5)
1:200 for IHC Abcam (ab48050) (1 mg/ml)
1:1000 for IHC Millipore (clone 2G10, neuronal | 05-559)
1:10000 for WB Sigma (clone AC-74, A5316 )
1:1000 for WB Abcam (ab1907) (1 mg/ml)
1:500 for IHC
1:100 for WB Abcam (ab85311) (0.1 mg/ml)
1:100 for IHC
1:200 for IHC Abcam (65080) (1 mg/ml)
1:250 for IHC Abcam (69090) (0.8 mg/ml)
1: 500 for IHC Abcam (10060) (1 mg/ml)
1:1000 for WB
1:500 for IHC Abcam (ab62631) (1 mg/ml)
1:100 for IHC Abcam (ab9498) (0.15 mg/ml)
1: 1000 for IHC Abcam (ab32457) (1 mg/ml)
1: 1000 for IHC Abcam (ab32570) (1 mg/ml)
Table 2 Alzheimer’s disease cases and age matched control brain samples
Case number Category Age Gender PM delay Cause of death
1 AD 83 Male 22.0 Bronchopneumonia
2 AD 80 Female 15.0 Cardiac failure
3 AD 74 Female 37.15 Gradual deterioration
4 AD 60 Male 12.9 Bronchopneumonia
5 AD 68 Male 17.5 AD, gradual decline
6 AD 81 Female 16.3 Aspiration pneumonia
7 Control 84 Female 31.45 Cancer, Heart failure
8 Control 81 Male 40.00 Chronic obstructive airway disease
9 Control 85 Male 43.35 Ca oesophagus
10 Control 73 Female 28.00 Ca bronchus
11 Control 83 Female 20.0 Bowel resection with complication
12 Control 88 Female 49.25 Chronic obstructive airway disease
AD = Alzheimer disease.
PM = post mortem.
Ca = carcinoma.
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In accordance with institutional guidelines for the
humane treatment of animals, mice were terminally
anaesthetised with carbon dioxide and culled. Unfixed
tissues were carefully dissected from various brain regions
from control and APP-tg mouse brains and snap frozen
in dry ice until analysed by Western blotting. For histo-
chemical analyses, animals were anesthetised with pento-
barbitone and flash-perfused transcardially with 0.9%
saline followed with 4% (v/v) paraformaldehyde (PFA)
in 0.1 M phosphate buffer (pH 7.4). Brains were sec-
tioned by microtome as described previously [56].
Free-floating sections were prepared (25 μm coronal
sections in 0.1 M PBS) through the entire olfactory
bulb, hippocampus, cortex, mid brain and cerebellum.
Sections were then stained by immunohistochemistry
as described below.
SDS-PAGE and Western blotting
Levels of hepcidin, ferroportin, ApoE and aβ-42 (6E10)
proteins were examined by Western blotting. Protein ly-
sates were prepared from hippocampus and SVZ of con-
trol, and AD brain (n = 6) as described previously [57]. 20
μg protein samples were separated using a 12-20% gradient
SDS-PAGE gel and transferred to polyvinylidene difluoride
(PVDF, pore sizes 0.45 μm or 0.2 μm for hepcidin) mem-
brane (Bio-Rad). The membrane was incubated with the
appropriate primary antibody in blocking buffer (5% non-
fat milk in 1 × tris buffer saline (TBS) for 24 h at 4˚C. The
membrane was then washed three times with 1 × TBS plus
0.1% Tween 20 (1× TBST) and incubated for 1 hour at
room temperature with HRP-conjugated secondary anti-
bodies (anti mouse IgG, 1:3000, DAKO) or anti-rabbit IgG
(1:3000; DAKO) antibodies). Finally, membranes were in-
cubated with ECL Plus chemiluminescence reagents andwere exposed to an X-ray film (Pierce). Levels of proteins
were estimated by densitometry analysis using the Gel
Analyzer module in the Image J program (NIH). Anti-actin
immunoblot was used to normalise protein loading. Simi-
larly protein lysates were prepared from cortex, hippocam-
pus and SVZ of control and APP-Tg mouse brains (n = 6)
and followed the same methodology.
Immunohistochemistry
PFA fixed tissues were first quenched with 5% hydrogen
peroxide and 20% methanol in 0.01M PBS for 30 min at
room temperature followed by three rinses for 10 min in
0.01M phosphate buffer saline (PBS). Non-specific bind-
ing sites were blocked using blocking buffer (0.1 M PBS,
0.3% Triton-X100, and 10% normal goat serum for poly-
clonal antibodies or 10% normal horse serum for mono-
clonal antibodies) for 1 h at room temperature. Tissue
sections were incubated overnight with the primary anti-
body diluted in blocking buffer (Table 1). Binding of the
primary antibody was detected using a biotinylated sec-
ondary antibody followed by an avidin-biotin complex
conjugated to peroxidase (Elite standard kit SK6100,
Vector Laboratories) and DAB substrate (ABC substrate
SK-4200, Vector Laboratories).
Immunofluorescence
Samples were blocked using blocking buffer (0.1 M PBS,
0.3% Triton X100, 10% normal donkey serum) for 1 hour
at room temperature and incubated overnight with the
primary antibody diluted in blocking buffer (Table 1).
Alexa Fluor-conjugated secondary antibodies were used
for detection, and samples were counterstained with
4′6-diamidino-2-phenylindole (DAPI, Sigma). Samples
were then mounted on glass slides with coverslips using
FluorSave (Calbiochem). All sections were processed
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periments are performed twice to assess reproducibil-
ity. To confirm the specificity of primary antibodies,
control experiment was performed with sections incu-
bated overnight in the absence of the primary antibody
or with the primary antibody, that was pre-incubated
with a blocking peptide (Figure 1n).Figure 1 (See legend on next page.)Microscopy
Bright field images were taken and quantified using
Lucia imaging software and a Leica FW 4000 upright
microscope equipped with SPOT digital camera. Fluor-
escence images were obtained using a Leica DM6000
wide field fluorescence microscope equipped with a
Leica FX350 camera and 20× and 40× objectives. Images
(See figure on previous page.)
Figure 1 Hepcidin and ferroportin protein levels decreased in AD brain. a. Western blot analysis of the brain from frontal cortex
demonstrated that a single 4 kDa band was clearly visible within all AD brain homogenates (lanes 4-6), in addition to a small proportion of control
cortical tissue (lane 1-3). Ferroportin and hepcidin antibodies detected a single 62 kDa and 2.8 kDa band respectively in controls (lane 1-3), with less
expression in AD. β-Actin loading control was used to normalize data. b. Densitometric analysis of the blots showed that there were significant
differences between AD and control brains for all three peptides assessed. Aβ42 levels were higher in the diseased brain compared to controls (p<0.005)
while hepcidin and ferroportin proteins were both significantly decreased (p<0.005 and p<0.01 respectively). c-n: Immunofluorescence in AD brains were
assessed compared to healthy controls. Double staining was performed with polyclonal hepcidin and monoclonal ferroportin antibodies and
counterstained with DAPI for nuclei. In the control brain superior frontal cortex hepcidin (c) and ferroportin (d) exhibited diffuse staining throughout the
tissue. Both proteins co-localised in astrocytes (e). In AD brain, both proteins were visible along the parenchymal surface of blood vessels
(f-g). Arrow indicates dual-labelling for hepcidin and ferroportin in small blood vessels (f-h). In the hippocampus of AD brains, hepcidin was visible in
neurons with limited co-localisation with Aβ (white arrow, i-l). Ferroportin expression appeared to be reduced in AD brains (j). However, hepcidin was
visible in damaged neurons (k). In control brain sections from mid temporal gyrus (MTG), hepcidin protein co-localised with GFAP (m). To evaluate
specificity of primary antibodies, a mouse brain section was incubated with secondary antibodies and DAPI, with the omission of the primary antibody.
There was no visible non-specific binding (n). Scale bar panels c-e and i-k & m 200 μm, f-h 100 μm, l = 25 μm.
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using Leica software. A Leica TCS SP2 confocal laser-
scanning microscope equipped with 40× and 63× objec-
tives was used to acquire high-resolution images.
Image and statistics analysis
All experiments were performed in triplicate. Western
blot and immunofluorescence images were quantified
using ImageJ software (NIH). For Western blots, the gel
analyser module was used. Selected bands were quanti-
fied based on their relative intensities, adjusted for
background with fold-change in intensity subjected to
statistical analysis as described below. Immunofluores-
cence was quantified using methods previously described
[58]. Values in the figures are expressed as mean ± SEM.
To determine the statistical significance, values were
analysed by Student’s t-test when comparing difference
between case (AD or APP-Tg brain) and control. A prob-
ability value of p<0.05 was considered to be statistically
significant.
Results
Decreased hepcidin and ferroportin protein levels in
AD brain
Analysis by Western blotting showed that Aβ42 levels
were increased in diseased brain as compared to controls
(P<0.005) while hepcidin and ferroportin proteins were
both significantly decreased (P<0.005 and P<0.01 re-
spectively, Figure 1a-b).
Brain sections from hippocampus, entorhinal cortex,
and superior frontal gyrus were then analysed by im-
munofluorescence using antibodies specific to Aβ42
(6E10), hepcidin and ferroportin. In superior frontal
gyrus and mid-temporal gyrus from control brains abun-
dant hepcidin and ferroportin were present in neurons
(Figure 1c-d) wherein the two proteins showed co-
localization, while hepcidin predominated in astrocytes
(Figure 1e). In AD brains extensive neuronal dege-
neration was observed and hepcidin and ferroportinstaining was seen in the neuropil and in damaged blood
vessels (Figure 1f-h). In sections of hippocampus from
AD brains that were stained for hepcidin and ferroportin
together with Aβ42, well established senile plaques were
observed and hepcidin staining was also seen in associ-
ation with fibrillary proteins (Figure 1i and l). Although
there was marked heterogeneity of staining between
different brain regions as well as between individual
cases, overall, ferroportin protein was significantly re-
duced in AD brains as compared to control (Figure 1j) as
evaluated by densitometric analysis (IMAGE J, Figure 2i-j,
p<0.005). Hepcidin expression in other glial cells was eval-
uated in sections from the mid temporal gyrus, showing
some co-localisation with the mature astrocytic marker
GFAP in astrocytes close to blood vessels (Figure 1m).
Glial cell types were then identified using confocal micros-
copy (Figure 2a-d, arrow) and in addition, hepcidin was
present in white matter tracts in this region, where it co-
localised with the mature oligodendrocytic marker MBP
(Figure 2f-h). Hepcidin protein was also visible in red
blood cells (Figure 2e, arrow).
Hepcidin expression in neuritic processes and amyloid
plaques
For more precise co-localization of hepcidin with spe-
cific cellular markers as well as amyloid plaques, we ex-
amined brain sections by confocal microscopy. As
shown in Figure 3, although uneven in its distribution in
the hippocampus hepcidin appeared to be expressed in
abnormal neuritic processes (Figure 3a). Scattered sur-
viving neurons within the plaques also demonstrated
hepcidin staining. Aβ42 staining revealed characteristic
neuritic plaques with a wagon-wheel morphology having
three components (i) an outer halo, (ii) an inner core
and (iii) DAPI positive nuclei (Figure 3b-c). In con-
trast, in the hippocampus (CA1 region) of normal
brain, hepcidin was present in pyramidal neurons,
showing co-localisation with Aβ42 in an endosomal/
lysosomal compartment (Figure 3d-f ).
Figure 2 Hepcidin protein present in glial cells. In control brain sections from mid temporal gyrus (MTG) hepcidin expression was in astrocytes
and co-localised with GFAP (white arrow, a-d). Hepcidin was visible in red blood cells close to blood vessels (e). Similarly in MTG in white matter tract
hepcidin co-localised with myelin basic protein (MBP), suggesting that hepcidin protein is expressed in oligodendrocytes as well as in astrocytes (f-h).
Scale bar panels a-c and e 30 μm, d 15 μm, f-h 20 μm. i. Hepcidin protein levels in the human superior frontal gyrus (SFG) of AD brains compared to
controls. Densitometric measurements of corrected total cell fluorescence adjusted against background (n=20, p<0.0001). j. Ferroportin protein level in
human SFG of AD brain compared to controls (n=20, p<0.0001) k. Hepcidin protein level in the dentate gyrus of APP-tg mice vs control (n= 20,
p<0.0001). ***denotes p<0.0001.
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mouse brain
As shown by immunohistochemistry hepcidin protein was
present in the mouse brain, observed in the olfactory bulb,
hippocampus, granule cells of the dentate gyrus, striatum,
choroid plexus and vascular endothelium of the lateral
ventricles (Figure 4a-e). Ferroportin was present in olfac-
tory glomerular neurons and in pyramidal neurons of thecortex (data not shown). Hepcidin immunoreactivity
was also present in the white matter tracts of the olfactory
bulb (Figure 4a) and corpus callosum, where it co-localised
with ferroportin (Figure 4f-h).
Hepcidin and ferroportin expression in APP-tg mice
Prominent accumulation of intraneuronal Aβ was pre-
sent in the frontal cortex, subiculum and CA1 of the
Figure 3 Hepcidin expression in neuritic processes and amyloid plaques. Confocal microscopic analysis of tissues from AD cases were
immunostained for Aβ (6E10) and hepcidin antibody and counterstained with DAPI for nuclei (Blue). In AD brains, accumulation of hepcidin
protein was visible in the intraneuronal compartment and in the abnormal fibrllary neuritic processes (a) and Aβ42 staining revealed
characteristic plaques (b) in the hippocampus. In AD brains, the neuritic plaques with a wagon-wheel morphology and a DAPI positive nuclei (c).
Diffuse Aβ rich plaques occasionally presented with areas of hepcidin accumulations (c). In the hippocampus of normal brains, hepcidin was
present in pyramidal neurons of CA1, in the endosomal/lysosomal compartment (d), minimal Aβ was visible in cell bodies (e) yet showed some
co-localisation with hepcidin in perinuclear locations (f). Scale bar a-f 25 μm.
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very mild/no plaque pathology (Figure 5a). By 4 months,
granular intraneuronal Aβ42 immunoreactivity was evi-
dent in pyramidal neurons (Figure 5b). In 6-month-old
animals, plaque pathology increased in the frontal cortex
(Figure 5c). By 10 months-old more severe pathology
was evident with the amyloid plaques increased in sizeand quantity and distributed throughout the cortex in
close proximity to blood vessels (Figure 5d-f ).
Early on in the disease process (2-6 months), hepcidin
was observed throughout the cortex, including the hippo-
campus, dentate gyrus, white matter tracts of the olfactory
bulb and corpus callosum of APP-tg mice. With disease
progression (10 months) hepcidin levels were reduced in
Figure 4 Hepcidin and ferroportin protein expression in control mouse brain. In control mouse brains, hepcidin protein was found in the
molecular layer of olfactory bulb (a), in the granule cells of dentate gyrus (b) and white matter tract of striatum (c). Hepcidin and ApoE present
in the epithelial cells of choroid plexus (d) and ependymal cells of the ventricular surface of lateral ventricle (e). The immunoreactivity of
oligodendrocytes was strong in white matter tracts, particularly in the corpus callosum (CC). Hepcidin (f) and FPN (g) expressed in the white
matter tract of CC and both proteins co-localised (h). Scale bar a, b & e 150 μm, c 20 μm, d 50 μm, f-h 25 μm.
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analysis (IMAGE J, Figure 2k, p<0.0001). In sections from
10 months-old animals stained additionally for Aβ42,
hepcidin was seen around the periphery of the maturing
plaques (Figure 5d-f). In the early stages (2 months) exten-
sive ferroportin staining was seen in the hippocampus(Figure 5g) and limited co-localisation with the neuronal
marker βIIIT was observed in some cells (Figure 5h-i).
Ferroportin levels were reduced as the disease progressed,
with expression limited to axons (Figure 5l) while hepcidin
expression was restricted to glial cells (astrocytes and oli-
godendrocytes) (Figure 5j-k).
Figure 5 Hepcidin and ferroportin expression in APP-tg mice. Immunofluorescence staining of intraneuronal Aβ and intracellular hepcidin
revealed an almost complete overlap in cortical neurons in two month old APP-tg mice (a), as well as in cortical extracellular plaques in 4-6
month old APP-tg mice (b, c indicated with white arrow). By 10 months, more severe pathology was evident with amyloid plaques increased in
size and quantity and distributed throughout the cortex in close proximity to blood vessels (d), olfactory bulb (e), dentate gyrus, subiculum and
the CA1 layer (f). With disease progression, hepcidin levels were reduced in the dentate gyrus (f, white arrow). At 2 months, FPN staining was
seen in all cortical neurons, co-localising with the neuronal marker βIII tubulin (g-i). Hepcidin was seen around the periphery of the maturing
plaques (j) along with glial activation (identified by GFAP, k), while with disease progression ferroportin levels were reduced with expression
limited to fibrillary axons (l, white arrow). Scale bar a-b 150 μm, c-g, 100 μm, j 150 μm, h-k 50 μm, l 25 μm.
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in mature amyloid plaques (10 months) sections were
stained with Aβ42 (6E10), hepcidin and DAPI, and ex-
amined by confocal microscopy. In the hippocampus(CA1), most of the neurons were positive for Aβ42, with
hepcidin granules visible in the cytosol of selected neu-
rons (Figure 6a-c). Although hepcidin was associated
with fibrillary protein in AD brains (Figure 3a and c), no
Figure 6 Hepcidin protein in mature amyloid plaques in APP-tg mouse brain. Confocal analysis of Aβ plaques and hepcidin
co-localisation in brains from 10 month-old APP-tg mice. In the hippocampus (CA1), hepcidin granules were visible in the cytosol of
selected neurons (a) and most of the neurons were positive for Aβ42 (b-c). Individual deposits were analysed by confocal laser
scanning microscopy and z-stacks were prepared. Hepcidin was present in surviving neurons in the DG, distributed around the
periphery of amyloid plaques in a form of a “halo” indicating wagon-wheel plaques (d-f). Arrowheads indicate dual-labeled plaques.
Scale bar a-f 25 μm.
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At higher magnification, hepcidin was present in sur-
viving neurons in the dentate gyrus, distributed around
the periphery of amyloid plaques in the form of a “halo”
(Figure 6d-f) similar to the distribution of BMP6, as de-
scribed by others [59].Ferritin accumulation in the APP-tg mouse brain during
disease progression
With increasing plaque formation in the frontal cortex
(Figure 7a), ferritin light-chain (FTL) accumulated in the
core of plaques, as seen in sections from a 10 month-old
animal (Figure 7b-d). To further assess the distribution
Figure 7 Ferritin accumulation in the APP-tg mouse brain. DAB immunostaining of 10 month-old APP-tg mice showed intraneuronal and
extracellular accumulation of Aβ peptides present throughout the brain, including in the hippocampus, dentate gyrus and all six layers of cortex
(a). Another section from cortex stained with ferritin light chain (FTL) showed immunoreactivity throughout cortex, as well as in plaques
(b-c) and centre core of the plaques (d). Double-label IFC staining of Aβ42 and FTL, seen close to the blood vessels in the hippocampus and
both proteins were detected throughout the brain (e-g). Ferritin heavy chain (FTH) was visible in a selected population of neurons in the
hippocampus but did not co-localise with Aβ42 (h-j). Hepcidin was seen in GFAP positive astrocytes (k-m). Protein levels were quantified by
Western blotting from 6 month-old APP-tg mice and age matched controls (n = 6). Aβ42 levels were higher in APP-tg mice compared to control
(p < 0.0002) while hepcidin levels were decreased (p<0.005). Ferroportin, ApoE and FTL levels, however, did not significantly change (n-o).
Scale bar a-b 250 μm, c 100 μm, d 25 μm, e-j 75 μm, k-m 30 μm.
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http://www.actaneurocomms.org/content/1/1/55of ferritin, brain sections (6 months) were stained with
Aβ42, FTL and ferritin heavy-chain (FTH) by immuno-
fluorescence. FTL was widely distributed throughout thebrain showing co-localisation with Aβ42 particularly in
the vicinity of blood vessels and ventricles (Figure 7e-g).
FTH expression was limited to hippocampal neurons
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the early stages of plaque formation (4-6 months),
GFAP-positive activated astrocytes that were seen sur-
rounding neuritic plaques demonstrated co-localisation
with hepcidin (Figure 7k-m).
Finally, protein steady state levels were measured and
compared by Western blotting using brain tissue (cortex
including hippocampus and dentate gyrus) from 6 month-
old APP-tg mice and age-matched controls (n = 6). Aβ42
levels were higher in APP-tg mice compared to con-
trol (p<0.0002) while hepcidin levels were decreased
(p<0.005). However significant changes were not seen
in levels of ferroportin, ApoE and FTL (Figure 7n-o).
Vascular endothelial damage in the APP-tg mouse
ApoE and Aβ are known to be cleared from the central
nervous system by efflux across the blood brain barrier
and this process is impaired in AD as a consequence of
vascular damage [18,55]. The expression of hepcidin and
ferroportin was therefore investigated specifically in the
vascular endothelium of the APP-tg mouse model. In
control mouse brain, the vascular endothelium was
characterised by strong hepcidin expression as shown
previously (Figure 4e) and also by the presence of
ferroportin that co-localised with hepcidin in the chor-
oid plexus (Figure 8b) and with PDGFβR1 in the endo-
thelium of lateral ventricles (Figure 8a). Co-localisation
was also noted between CD31 and hepcidin in the endo-
thelial lining of the blood vessels (Figure 8c). In 4-month-
old APP-tg mice, vascular damage was not evident and
co-localisation between ApoE and ferroportin was seen
in the endothelium of the choroid plexus and lateral
ventricles (Figure 8d).
By 10 months APP-tg mice showed widespread endo-
thelium damage, loss of cellular integrity and, in some
sections, loss of endothelium in the wall of ventricles
(Figure 8e-i). Sections were also stained with CD31
(endothelium marker) and a pericyte marker (PDGFβR1)
to confirm the appropriate staining pattern in controls
(Figure 8f-k) and extensive endothelial disruption in the
APP-tg mouse model (Figure 8e-k). Both hepcidin and
ApoE were found in APP-tg mice close to the blood
vessels (Figure 8l).
Hepcidin co-staining with haem-rich deposit and red
blood cells in AD brain
Haem-rich deposits and red blood cells were scattered
throughout the parenchyma in AD brain in accordance
with previously reported observations [60]. We also
noted a close relationship of haem-rich deposits to small
blood vessels in all cases examined (Figure 9a). Red
blood cells demonstrating typical biconcave morphology
within large blood vessels co-localized with hepcidin,
while a faint ferroportin signal was observed (Figure 9c,marked with arrow). Intravascular red blood cells appear
yellow in the figure resulting from a combination of red
haem colour and green signal from hepcidin (Figure 9a-b).
Discussion
The pathological features of the common neurodegener-
ative conditions, Alzheimer’s disease, Parkinson’s disease
and multiple sclerosis are all known to be associated
with iron dysregulation in regions of the brain where the
specific pathology is most highly expressed [21,25]. The
diversity of the pathological processes involved make it
unlikely that there is a primary abnormality of brain iron
metabolism common to these diseases, although this is
the case with a group of rare genetic disorders character-
ized by neurodegeneration with brain iron accumulation
(NBIA), [61]. Even if the abnormalities in iron metabol-
ism in common neurodegenerative disorders are second-
ary phenomena the finding that iron-related oxidative
damage in Alzheimer’s disease is an early event in the
disease process [29,62] suggests that the control of iron
levels in the brain remains a worthwhile therapeutic
target [63].
In the present study the expression of proteins that
play a central role in maintaining systemic iron homeo-
stasis, hepcidin and its receptor, ferroportin, was investi-
gated in human AD brains and in the APP transgenic
mouse model to further characterize abnormalities of
iron metabolism. Hepcidin and ferroportin protein were
found to be widely distributed in normal human and
mouse brain but levels were decreased significantly in
AD brains and in the later stages of the mouse model.
The expression of ferroportin protein has been reported
to be decreased by ischaemia [64,65] and inflammation
in the rat cortex [66,67] and in primary cultures of rat
brain cells [68,69]. The down-regulation of ferroportin
by inflammatory stimuli in cells derived from the brain
mirrors the findings in multiple cell types in systemic
iron metabolism [70-72]. The primary pathology of AD,
that of protein misfolding [5,10], is accompanied by
other pathological processes, notably vascular damage
with associated ischaemic changes [73,74] and inflam-
mation [75,76] and we believe that the reduction in
ferroportin expression found in the present study is
likely to be a secondary phenomenon caused by these
factors that clearly contribute to AD pathogenesis
[77,78]. Ferroportin is also down-regulated when bound
by hepcidin at the cell surface, an event that leads to the
internalization and degradation of the iron carrier [35].
This was observed in rat brain when the expression of
ferroportin was reduced following the intra-ventricular
administration of hepcidin [79,80] or when hepcidin was
added directly to primary cultures of neurons, astrocytes
and microglia [69]. We found that hepcidin levels were
reduced in human and mouse brains exhibiting severe
Figure 8 Vascular endothelial damage in the APP-tg mouse. Immunofluorescence staining of hepcidin and ferroportin with endothelial
markers CD31 and PDGFβR1 was performed using brain sections from lateral ventricles, choroid plexus and blood vessels. In control mice,
hepcidin staining was detected in ependymal cells of lateral ventricles at 4 months (a), the choroid plexus at 10 months-old where hepcidin and
FPN both co-localised in epithelial cells, with higher FPN expression on the ventricular side (white arrow, b). Hepcidin was present in endothelial
cells in blood vessels (c). Hepcidin staining was visible in epithelial cells of choroid plexus where as ApoE was found in the blood vessel wall (c).
There was no vessel damage noticed in 4 months old APP-tg mouse choroid plexus stained with ApoE and FPN (d), whereas by 10 months
more vascular damage was apparent (e). Similarly sections close to the lateral ventricle of APP-Tg mice were stained with ApoE and FPN (h),
ApoE and hepcidin (i) indicating extensive endothelial damage. Blood vessel integrity was assessed with CD31 and PDGFβR1 markers, with intact
endothelium and pericytes were observed in controls (g) while badly damaged endothelia was seen in APP-tg mice at 10 months (f) and (j).
In another section from APP-tg thalamus stained with ApoE and CD31 showed a complete loss of endothelial layer at 10 months (k). Hepcidin
and ApoE co-localised in large blood vessels (l). Scale bar a-b, 100 μm, c 25 μm, d-f and h-k 75 μm, g and l 50 μm.
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Figure 9 Hepcidin visible in haem-rich deposit and red blood cells in AD brain. AD (SFG) human brain sections double-labeled with
hepcidin and ferroportin by IFC and counterstained with DAPI. Limited hepcidin and FPN protein expression was seen throughout brain
parenchyma with some autofluorescent puncta due to haem rich deposits (HRD, a). Higher magnification showed both proteins in HRD,
visible in small arterioles (b). A single labelled image showed RBCs with typical biconcave morphology were also positive for hepcidin (c).
Scale bar: a 200 μm, b 50 μm, c 15 μm.
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as shown in the mouse model, hepcidin levels did not
differ significantly from controls and the interaction
with ferroportin as seen in cortical neurons by immu-
nohistochemical staining could contribute to the de-
cline in levels of the iron carrier. Inflammation in AD [75]
could be a further reason for the increase in hepcidin
levels as in the systemic environment hepcidin synthesisby hepatocytes is transcriptionally regulated by IL-6
through the STAT-3 signalling pathway [81]. Interest-
ingly in the dentate gyrus of the APP mouse and in
AD brains we found that hepcidin was distributed around
the periphery of amyloid plaques and in surviving
neurons, in a similar distribution to that of IL-6 around
plaques and in large cortical neurons reported previously
in AD [82].
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localised in cortical neurons in control brains is con-
sistent with a role in for these protein in regulating
neuronal iron release [35]. However, neither the con-
stitutive loss of hepcidin through gene mutations in either
human [83] or mouse models of haemochromatosis
[84,85] or the targeted loss of ferroportin in the brain [45]
appear to cause cerebral or cerebellar dysfunction and a
role for hepcidin and ferroportin in the brain is currently
undefined. Our finding that hepcidin protein was widely
distributed in normal human and mouse brain is consist-
ent with previous reports [64,86] and raises the question
of the origin of this protein given that hepcidin mRNA
was not consistently detected by in situ hybridization in
normal mouse brain [86]. Hepcidin is a gene-encoded
antimicrobial peptide structurally related to members of
the defensin and protegrin families [87], most of which
are cationic, a property that facilitates adsorption and in-
sertion into anionic bacterial cell walls [87]. Cationic pep-
tides also cross mammalian cell membranes [88] and the
blood brain barrier [89-91] and it is possible that hepcidin
may cross the vascular endothelium to enter the brain
interstitium.
Direct evidence for iron mishandling in AD brain
comes from the histochemical demonstration of non-
haem iron deposits in senile plaques [21,92,93] and Aβ
plaques in APP mice [94] and iron levels were also
found to be increased in neurofibrillary tangles and
plaques using laser microprobe mass analysis [95] and
particle-induced X-ray emission [96]. It is not clear
whether this represents increased deposition of iron and
other transition metals [97] in the region of plaques or a
more general increase as iron levels have not been found
to be consistently increased in AD brains [98-100] com-
pared to age-matched controls. Increased immunoreac-
tivity for the iron storage protein ferritin, within and
around plaques [101,102] is further evidence of a local
increase in iron as this protein is regulated primarily at
the translational level through the binding of iron regu-
latory proteins to ferritin H- and L-chain mRNAs [34].
Consistent with these findings in human AD brains, we
found strong immunoreactivity for ferritin L-chain in
maturing plaques in the later stages of the APP mouse
while early on in the disease process this isoform was
widely distributed throughout the brain in association
with Aβ42 in the vicinity of blood vessels. There is
recent evidence that ferritin L-chain may have a fun-
damental role in plaque pathology by binding to and
stabilising PEN-2, a functional component of γ-secretase,
the enzyme that cleaves APP to generate Aβ [103]. Build-
ing on this observation it has been suggested that in-
creased levels of iron and, hence, ferritin L-chain may lead
to increased production of Aβ [34,103]. The excess iron in
plaques and associated increase in ferritin L-chain, theiron-storage isoform [34], is likely a secondary event
resulting from a failure to utilise iron by dead and dying
neurons. The suggestion that ferritin L-chain may lead to
increased production of Aβ by increasing the activity of γ-
secretase [103] would be consistent with a role for iron
in promoting and maintaining plaque pathology. In
agreement with earlier reports [25,104] expression of
ferritin H-chain was restricted to pyramidal neurons
of the hippocampus.
Recent studies into the cause of vascular dysfunction
in neurodegenerative diseases such as AD [73] suggest
that the mechanisms include breakdown of the blood-
brain barrier as a result of loss of pericytes [2,73,105],
hypo-perfusion leading to hypoxia and brain ischaemia
[74] and endothelial dysfunction [77]. Furthermore,
these abnormalities in vascular structure and function
were recapitulated in the arcAβ mouse model of AD
[106] while in the late stages of the APP-tg model used
in the present study, loss of pericytes and extensive
endothelial disruption was seen confirming the presence
of severe vascular pathology. Loss of vascular integrity is
also responsible for abnormal iron accumulation in
addition to ferritin in AD brains in the form of haem-
positive granular deposits. These have been demon-
strated in aged brains in association with senile plaques
and result from capillary bleeds or micro-haemorrhages
[60,107]. In AD brains where extensive neuronal damage
was present, although levels of hepcidin and ferroportin
were reduced, both proteins were found in association
with haem-positive granular deposits in the region of
damaged blood vessels.
Conclusions
Our results describe the progressive changes and dy-
namic interplay of iron homeostasis, vascular changes
and neuronal degeneration in AD. In conclusion, as vas-
cular damage with associated ischaemic change is wide-
spread in AD brains it is likely that the reasons for a
reduction in ferroportin levels are multifactorial but
include cerebral ischaemia, inflammation, the loss of neu-
rons due to the well characterised protein misfolding,
senile plaque formation and possibly the ageing process it-
self. Progressive accumulation of ferritin light chain in
the core of amyloid plaques of the APP tg mouse im-
plies that there is an imbalance in iron utilization and
release.Abbreviations
AD: Alzheimer’s disease; Aβ: Amyloid-β-peptide; ApoE: Apolipoprotein E;
APP: Amyloid precursor protein; APP-tg: APP transgenic mouse; βIIIT: β
Tubulin type III; BSA: Bovine serum albumin; CA: Cornu ammonis;
CP: Choroid plexus; CVD: Cerebrovascular dementia; DG: Dentate gyrus;
FTL: Ferritin light chain; FTH: Ferritin heavy chain; FPN: Ferroportin;
IF: Immunofluorescence; IHC: Immunohistochemistry; NFT: Neurofibrillary
tangles; OB: Olfactory bulb; PAGE: Polyacrylamide gel electrophoresis;
Raha et al. Acta Neuropathologica Communications 2013, 1:55 Page 17 of 19
http://www.actaneurocomms.org/content/1/1/55PBS: Phosphate buffered saline; PD: Parkinson’s disease; SDS: Sodium dodecyl
sulphate; SFG: Superior frontal gyrus; WB: Western blotting.
Competing interests
The authors declared that they have no competing interests.
Authors’ contributions
AAR performed all experiments, including characterization of APP-tg mouse
model and confocal microscopy. RAV and RPF contributed to the hypothesis
development and implications of vascular defect in AD brain and edited the
manuscript. AB and RRC contributed to the hypothesis development,
performed study design, critically evaluated the results and wrote the
manuscript. All authors read and approved the final manuscript.
Acknowledgements
We thank for Professor James Fawcett and Dr Simon Stott for critically
reading the manuscript and endless encouragement. We also acknowledge
Abcam (Cambridge, UK) for providing iron-related antibodies. This study was
supported by the John Van Geest foundation, Scholl Foundation, and the
Medical Research Council, UK.
Author details
1John Van Geest Centre for Brain Repair, Department of Clinical
Neuroscience, University of Cambridge, Cambridge CB2 0PY, UK.
2Department of Neurology, University of Louisville School of Medicine,
Louisville, KY, USA. 3Institute of Liver Studies, King’s College Hospital, London,
UK.
Received: 5 July 2013 Accepted: 25 August 2013
Published: 3 September 2013
References
1. Zlokovic BV: The blood-brain barrier in health and chronic
neurodegenerative disorders. Neuron 2008, 57(2):178–201.
2. Sengillo JD, Winkler EA, Walker CT, Sullivan JS, Johnson M, Zlokovic BV:
Deficiency in mural vascular cells coincides with blood-brain barrier
disruption in Alzheimer’s disease. Brain Pathol 2013, 23(3):303–310.
3. Shi J, Perry G, Smith MA, Friedland RP: Vascular abnormalities: the
insidious pathogenesis of Alzheimer’s disease. Neurobiol Aging 2000,
21(2):357–361.
4. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M:
Alpha-synuclein in Lewy bodies. Nature 1997, 388(6645):839–840.
5. Goedert M, Spillantini MG: A century of Alzheimer’s disease. Science 2006,
314(5800):777–781.
6. Bayer TA, Wirths O: Intraneuronal Abeta as a trigger for neuron loss: can
this be translated into human pathology? Biochem Soc Trans 2011,
39(4):857–861.
7. Hardy JA, Higgins GA: Alzheimer’s disease: the amyloid cascade
hypothesis. Science 1992, 256(5054):184–185.
8. Selkoe DJ: Clearing the brain’s amyloid cobwebs. Neuron 2001,
32(2):177–180.
9. Selkoe DJ, Bell DS, Podlisny MB, Price DL, Cork LC: Conservation of brain
amyloid proteins in aged mammals and humans with Alzheimer’s
disease. Science 1987, 235(4791):873–877.
10. Hardy J, Selkoe DJ: The amyloid hypothesis of Alzheimer’s disease:
progress and problems on the road to therapeutics. Science 2002,
297(5580):353–356.
11. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I,
Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM,
Sabatini BL, Selkoe DJ: Amyloid-beta protein dimers isolated directly
from Alzheimer’s brains impair synaptic plasticity and memory.
Nat Med 2008, 14(8):837–842.
12. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small
GW, Roses AD, Haines JL, Pericak-Vance MA: Gene dose of apolipoprotein
E type 4 allele and the risk of Alzheimer’s disease in late onset families.
Science 1993, 261(5123):921–923.
13. Mahley RW, Weisgraber KH, Huang Y: Apolipoprotein E4: a causative factor
and therapeutic target in neuropathology, including Alzheimer’s disease.
Proc Natl Acad Sci U S A 2006, 103(15):5644–5651.14. Kalaria RN, Cohen DL, Premkumar DR: Apolipoprotein E alleles and brain
vascular pathology in Alzheimer’s disease. Ann N Y Acad Sci 1996,
777:266–270.
15. Premkumar DR, Cohen DL, Hedera P, Friedland RP, Kalaria RN:
Apolipoprotein E-epsilon4 alleles in cerebral amyloid angiopathy and
cerebrovascular pathology associated with Alzheimer’s disease. Am J
Pathol 1996, 148(6):2083–2095.
16. Elshourbagy NA, Liao WS, Mahley RW, Taylor JM: Apolipoprotein E mRNA is
abundant in the brain and adrenals, as well as in the liver, and is
present in other peripheral tissues of rats and marmosets. Proc Natl Acad
Sci U S A 1985, 82(1):203–207.
17. Ang LS, Cruz RP, Hendel A, Granville DJ: Apolipoprotein E, an
important player in longevity and age-related diseases. Exp Gerontol
2008, 43(7):615–622.
18. Bell RD, Sagare AP, Friedman AE, Bedi GS, Holtzman DM, Deane R, Zlokovic
BV: Transport pathways for clearance of human Alzheimer’s amyloid
beta-peptide and apolipoproteins E and J in the mouse central nervous
system. J Cereb Blood Flow Metab 2007, 27(5):909–918.
19. Deane R, Sagare A, Hamm K, Parisi M, Lane S, Finn MB, Holtzman DM,
Zlokovic BV: apoE isoform-specific disruption of amyloid beta peptide
clearance from mouse brain. J Clin Invest 2008, 118(12):4002–4013.
20. Martel CL, Mackic JB, Matsubara E, Governale S, Miguel C, Miao W, McComb
JG, Frangione B, Ghiso J, Zlokovic BV: Isoform-specific effects of
apolipoproteins E2, E3, and E4 on cerebral capillary sequestration and
blood-brain barrier transport of circulating Alzheimer’s amyloid beta.
J Neurochem 1997, 69(5):1995–2004.
21. Raven EP, Lu PH, Tishler TA, Heydari P, Bartzokis G: Increased iron levels
and decreased tissue integrity in hippocampus of Alzheimer's disease
detected In vivo with magnetic resonance imaging. J Alzheimers Dis 2013,
37(1):127–136.
22. Grundke-Iqbal I, Fleming J, Tung YC, Lassmann H, Iqbal K, Joshi JG: Ferritin
is a component of the neuritic (senile) plaque in Alzheimer dementia.
Acta Neuropathol 1990, 81(2):105–110.
23. Todorich BM, Connor JR: Redox metals in Alzheimer’s disease. Ann N Y
Acad Sci 2004, 1012:171–178.
24. Smith MA, Perry G, Pryor WA: Causes and consequences of oxidative
stress in Alzheimer’s disease. Free Radic Biol Med 2002, 32(11):1049.
25. Zecca L, Youdim MB, Riederer P, Connor JR, Crichton RR: Iron, brain ageing
and neurodegenerative disorders. Nat Rev Neurosci 2004, 5(11):863–873.
26. Bishop GM, Robinson SR: Human Abeta1-42 reduces iron-induced toxicity
in rat cerebral cortex. J Neurosci Res 2003, 73(3):316–323.
27. Atamna H: Heme binding to Amyloid-beta peptide: mechanistic role in
Alzheimer’s disease. J Alzheimers Dis 2006, 10(2–3):255–266.
28. Bergamini E, Bizzarri R, Cavallini G, Cerbai B, Chiellini E, Donati A, Gori Z,
Manfrini A, Parentini I, Signori F, Tamburini I: Ageing and oxidative stress: a
role for dolichol in the antioxidant machinery of cell membranes?
J Alzheimers Dis 2004, 6(2):129–135.
29. Smith MA, Harris PL, Sayre LM, Perry G: Iron accumulation in Alzheimer
disease is a source of redox-generated free radicals. Proc Natl Acad Sci
U S A 1997, 94(18):9866–9868.
30. Ganz T: Hepcidin, a key regulator of iron metabolism and mediator of
anemia of inflammation. Blood 2003, 102(3):783–788.
31. Ganz T: Hepcidin and iron regulation, 10 years later. Blood 2011,
117(17):4425–4433.
32. Yang F, Liu XB, Quinones M, Melby PC, Ghio A, Haile DJ: Regulation of
reticuloendothelial iron transporter MTP1 (Slc11a3) by inflammation.
J Biol Chem 2002, 277(42):39786–39791.
33. McKie AT, Barrow D, Latunde-Dada GO, Rolfs A, Sager G, Mudaly E,
Mudaly M, Richardson C, Barlow D, Bomford A, Peters TJ, Raja KB,
Shirali S, Hediger MA, Farzaneh F, Simpson RJ: An iron-regulated ferric
reductase associated with the absorption of dietary iron. Science
2001, 291(5509):1755–1759.
34. Hentze MW, Muckenthaler MU, Galy B, Camaschella C: Two to tango:
regulation of Mammalian iron metabolism. Cell 2010, 142(1):24–38.
35. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM,
Ganz T, Kaplan J: Hepcidin regulates cellular iron efflux by binding
to ferroportin and inducing its internalization. Science 2004,
306(5704):2090–2093.
36. De Domenico I, Ward DM, di Patti MC, Jeong SY, David S, Musci G, Kaplan J:
Ferroxidase activity is required for the stability of cell surface ferroportin
in cells expressing GPI-ceruloplasmin. EMBO J 2007, 26(12):2823–2831.
Raha et al. Acta Neuropathologica Communications 2013, 1:55 Page 18 of 19
http://www.actaneurocomms.org/content/1/1/5537. Krause A, Neitz S, Magert HJ, Schulz A, Forssmann WG, Schulz-Knappe P,
Adermann K: LEAP-1, a novel highly disulfide-bonded human peptide,
exhibits antimicrobial activity. FEBS Lett 2000, 480(2–3):147–150.
38. Park CH, Valore EV, Waring AJ, Ganz T: Hepcidin, a urinary antimicrobial
peptide synthesized in the liver. J Biol Chem 2001, 276(11):7806–7810.
39. Pigeon C, Ilyin G, Courselaud B, Leroyer P, Turlin B, Brissot P, Loreal O: A
new mouse liver-specific gene, encoding a protein homologous to
human antimicrobial peptide hepcidin, is overexpressed during iron
overload. J Biol Chem 2001, 276(11):7811–7819.
40. Cheng PP, Jiao XY, Wang XH, Lin JH, Cai YM: Hepcidin expression in
anemia of chronic disease and concomitant iron-deficiency anemia. Clin
Exp Med 2011, 11(1):33–42.
41. Papanikolaou G, Tzilianos M, Christakis JI, Bogdanos D, Tsimirika K,
MacFarlane J, Goldberg YP, Sakellaropoulos N, Ganz T, Nemeth E: Hepcidin
in iron overload disorders. Blood 2005, 105(10):4103–4105.
42. Abboud S, Haile DJ: A novel mammalian iron-regulated protein involved
in intracellular iron metabolism. J Biol Chem 2000, 275(26):19906–19912.
43. McKie AT, Marciani P, Rolfs A, Brennan K, Wehr K, Barrow D, Miret S,
Bomford A, Peters TJ, Farzaneh F, Hediger MA, Hentze MW, Simpson RJ: A
novel duodenal iron-regulated transporter, IREG1, implicated in the
basolateral transfer of iron to the circulation. Mol Cell 2000, 5(2):299–309.
44. Donovan A, Brownlie A, Zhou Y, Shepard J, Pratt SJ, Moynihan J, Paw BH,
Drejer A, Barut B, Zapata A, Law TC, Brugnara C, Lux SE, Pinkus GS, Pinkus JL,
Kingsley PD, Palis J, Fleming MD, Andrews NC, Zon LI: Positional cloning of
zebrafish ferroportin1 identifies a conserved vertebrate iron exporter.
Nature 2000, 403(6771):776–781.
45. Donovan A, Lima CA, Pinkus JL, Pinkus GS, Zon LI, Robine S, Andrews NC:
The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis.
Cell Metab 2005, 1(3):191–200.
46. Wu LJ, Leenders AG, Cooperman S, Meyron-Holtz E, Smith S, Land W, Tsai
RY, Berger UV, Sheng ZH, Rouault TA: Expression of the iron transporter
ferroportin in synaptic vesicles and the blood-brain barrier. Brain Res
2004, 1001(1–2):108–117.
47. Burdo JR, Menzies SL, Simpson IA, Garrick LM, Garrick MD, Dolan KG, Haile
DJ, Beard JL, Connor JR: Distribution of divalent metal transporter 1 and
metal transport protein 1 in the normal and Belgrade rat. J Neurosci Res
2001, 66(6):1198–1207.
48. Moos T, Rosengren Nielsen T: Ferroportin in the postnatal rat brain:
implications for axonal transport and neuronal export of iron. Semin
Pediatr Neurol 2006, 13(3):149–157.
49. Moos T, Skjoerringe T, Gosk S, Morgan EH: Brain capillary endothelial cells
mediate iron transport into the brain by segregating iron from
transferrin without the involvement of divalent metal transporter 1.
J Neurochem 2006, 98(6):1946–1958.
50. Duce JA, Tsatsanis A, Cater MA, James SA, Robb E, Wikhe K, Leong SL, Perez
K, Johanssen T, Greenough MA, Cho HH, Galatis D, Moir RD, Masters CL,
McLean C, Tanzi RE, Cappai R, Barnham KJ, Ciccotosto GD, Rogers JT, Bush
AI: Iron-export ferroxidase activity of beta-amyloid precursor protein is
inhibited by zinc in Alzheimer’s disease. Cell 2010, 142(6):857–867.
51. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F,
Cole G: Correlative memory deficits, Abeta elevation, and amyloid
plaques in transgenic mice. Science 1996, 274(5284):99–102.
52. Kumar-Singh S, Pirici D, McGowan E, Serneels S, Ceuterick C, Hardy J, Duff K,
Dickson D, Van Broeckhoven C: Dense-core plaques in Tg2576 and PSAPP
mouse models of Alzheimer’s disease are centered on vessel walls.
Am J Pathol 2005, 167(2):527–543.
53. Chuang JY, Lee CW, Shih YH, Yang T, Yu L, Kuo YM: Interactions between
amyloid-beta and hemoglobin: implications for amyloid plaque
formation in Alzheimer’s disease. PLoS One 2012, 7(3):e33120.
54. Masliah E, Sisk A, Mallory M, Mucke L, Schenk D, Games D: Comparison of
neurodegenerative pathology in transgenic mice overexpressing V717F
beta-amyloid precursor protein and Alzheimer’s disease. J Neurosci 1996,
16(18):5795–5811.
55. Winkler EA, Sengillo JD, Bell RD, Wang J, Zlokovic BV: Blood-spinal cord
barrier pericyte reductions contribute to increased capillary permeability.
J Cereb Blood Flow Metab 2012, 32(10):1841–1852.
56. Zhao JW, Raha-Chowdhury R, Fawcett JW, Watts C: Astrocytes and
oligodendrocytes can be generated from NG2+ progenitors after
acute brain injury: intracellular localization of oligodendrocyte
transcription factor 2 is associated with their fate choice. Eur J
Neurosci 2009, 29(9):1853–1869.57. Raha-Chowdhury R, Andrews SR, Gruen JR: CAT 53: a protein phosphatase
1 nuclear targeting subunit encoded in the MHC Class I region strongly
expressed in regions of the brain involved in memory, learning, and
Alzheimer’s disease. Brain Res Mol Brain Res 2005, 138(1):70–83.
58. Burgess A, Vigneron S, Brioudes E, Labbe JC, Lorca T, Castro A: Loss of
human Greatwall results in G2 arrest and multiple mitotic defects due to
deregulation of the cyclin B-Cdc2/PP2A balance. Proc Natl Acad Sci U S A
2010, 107(28):12564–12569.
59. Crews L, Adame A, Patrick C, Delaney A, Pham E, Rockenstein E, Hansen L,
Masliah E: Increased BMP6 levels in the brains of Alzheimer’s disease
patients and APP transgenic mice are accompanied by impaired
neurogenesis. J Neurosci 2010, 30(37):12252–12262.
60. Cullen KM, Kocsi Z, Stone J: Pericapillary haem-rich deposits: evidence for
microhaemorrhages in aging human cerebral cortex. J Cereb Blood Flow
Metab 2005, 25(12):1656–1667.
61. Schneider SA, Hardy J, Bhatia KP: Syndromes of neurodegeneration with
brain iron accumulation (NBIA): an update on clinical presentations,
histological and genetic underpinnings, and treatment considerations.
Mov Disord 2012, 27(1):42–53.
62. Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj EK, Jones PK,
Ghanbari H, Wataya T, Shimohama S, Chiba S, Atwood CS, Petersen RB,
Smith MA: Oxidative damage is the earliest event in Alzheimer disease.
J Neuropathol Exp Neurol 2001, 60(8):759–767.
63. Bonda DJ, Lee HG, Blair JA, Zhu X, Perry G, Smith MA: Role of metal
dyshomeostasis in Alzheimer’s disease. Metallomics 2011, 3(3):267–270.
64. Ding H, Yan CZ, Shi H, Zhao YS, Chang SY, Yu P, Wu WS, Zhao CY, Chang
YZ, Duan XL: Hepcidin is involved in iron regulation in the ischemic
brain. PLoS One 2011, 6(9):e25324.
65. Li H, Rose MJ, Tran L, Zhang J, Miranda LP, James CA, Sasu BJ: Development
of a method for the sensitive and quantitative determination of hepcidin
in human serum using LC-MS/MS. J Pharmacol Toxicol Methods 2009,
59(3):171–180.
66. Andersen MV, PRg C, Jensen MD, Lichota J, Moos T: A decrease in
neuronal ferroportin accompanies chronic brain inflammation with iron
deposition. In Meeting of the International BioIron Society; 2013.
67. Malik IA, Naz N, Sheikh N, Khan S, Moriconi F, Blaschke M, Ramadori G:
Comparison of changes in gene expression of transferrin receptor-1 and
other iron-regulatory proteins in rat liver and brain during acute-phase
response. Cell Tissue Res 2011, 344(2):299–312.
68. Rathore KI, Redensek A, David S: Iron homeostasis in astrocytes and
microglia is differentially regulated by TNF-alpha and TGF-beta1.
Glia 2012, 60(5):738–750.
69. Urrutia P, Aguirre P, Esparza A, Tapia V, Mena NP, Arredondo M, Gonzalez-
Billault C, Nunez MT: Inflammation alters the expression of DMT1, FPN1
and hepcidin, and it causes iron accumulation in central nervous system
cells. J Neurochem 2013, 126(4):541–549.
70. Liu XB, Nguyen NB, Marquess KD, Yang F, Haile DJ: Regulation of hepcidin
and ferroportin expression by lipopolysaccharide in splenic
macrophages. Blood Cells Mol Dis 2005, 35(1):47–56.
71. Ludwiczek S, Aigner E, Theurl I, Weiss G: Cytokine-mediated regulation of
iron transport in human monocytic cells. Blood 2003, 101(10):4148–4154.
72. Sheikh N, Dudas J, Ramadori G: Changes of gene expression of iron
regulatory proteins during turpentine oil-induced acute-phase response
in the rat. Lab Invest 2007, 87(7):713–725.
73. Iadecola C: The overlap between neurodegenerative and vascular factors
in the pathogenesis of dementia. Acta Neuropathol 2010, 120(3):287–296.
74. Zlokovic BV: Neurovascular pathways to neurodegeneration in Alzheimer’s
disease and other disorders. Nat Rev Neurosci 2011, 12(12):723–738.
75. Eikelenboom P, Hoozemans JJ, Veerhuis R, van Exel E, Rozemuller AJ, van
Gool WA: Whether, when and how chronic inflammation increases the
risk of developing late-onset Alzheimer’s disease. Alzheimer’s Res Ther
2012, 4(3):1–9.
76. Rogers J, Cooper NR, Webster S, Schultz J, McGeer PL, Styren SD, Civin WH,
Brachova L, Bradt B, Ward P, et al: Complement activation by beta-amyloid
in Alzheimer disease. Proc Natl Acad Sci U S A 1992, 89(21):10016–10020.
77. Grammas P: Neurovascular dysfunction, inflammation and endothelial
activation: implications for the pathogenesis of Alzheimer’s disease.
J Neuroinflammation 2011, 8:26.
78. Zotova E, Nicoll JA, Kalaria R, Holmes C, Boche D: Inflammation in
Alzheimer’s disease: relevance to pathogenesis and therapy. Alzheimers
Res Ther 2010, 2(1):1.
Raha et al. Acta Neuropathologica Communications 2013, 1:55 Page 19 of 19
http://www.actaneurocomms.org/content/1/1/5579. Li L, Holscher C, Chen BB, Zhang ZF, Liu YZ: Hepcidin treatment
modulates the expression of divalent metal transporter-1, ceruloplasmin,
and ferroportin-1 in the rat cerebral cortex and hippocampus. Biol Trace
Elem Res 2011, 143(3):1581–1593.
80. Wang SM, Fu LJ, Duan XL, Crooks DR, Yu P, Qian ZM, Di XJ, Li J, Rouault TA,
Chang YZ: Role of hepcidin in murine brain iron metabolism. Cell Mol Life
Sci 2010, 67(1):123–133.
81. Pietrangelo A, Dierssen U, Valli L, Garuti C, Rump A, Corradini E, Ernst M,
Klein C, Trautwein C: STAT3 is required for IL-6-gp130-dependent
activation of hepcidin in vivo. Gastroenterology 2007, 132(1):294–300.
82. Strauss S, Bauer J, Ganter U, Jonas U, Berger M, Volk B: Detection of
interleukin-6 and alpha 2-macroglobulin immunoreactivity in cortex
and hippocampus of Alzheimer’s disease patients. Lab Invest 1992,
66(2):223–230.
83. Pietrangelo A: Hereditary hemochromatosis: pathogenesis, diagnosis, and
treatment. Gastroenterology 2010, 139(2):393–408. 408 e1-2.
84. Moos T, Trinder D, Morgan EH: Cellular distribution of ferric iron, ferritin,
transferrin and divalent metal transporter 1 (DMT1) in substantia nigra
and basal ganglia of normal and beta2-microglobulin deficient mouse
brain. Cell Mol Biol (Noisy-le-grand) 2000, 46(3):549–561.
85. Wallace DF, Summerville L, Crampton EM, Frazer DM, Anderson GJ,
Subramaniam VN: Combined deletion of Hfe and transferrin receptor 2 in
mice leads to marked dysregulation of hepcidin and iron overload.
Hepatology 2009, 50(6):1992–2000.
86. Zechel S, Huber-Wittmer K, von Bohlen und Halbach O: Distribution of the
iron-regulating protein hepcidin in the murine central nervous system.
J Neurosci Res 2006, 84(4):790–800.
87. Bulet P, Stocklin R, Menin L: Anti-microbial peptides: from invertebrates to
vertebrates. Immunol Rev 2004, 198:169–184.
88. Drin G, Cottin S, Blanc E, Rees AR, Temsamani J: Studies on the
internalization mechanism of cationic cell-penetrating peptides. J Biol
Chem 2003, 278(33):31192–31201.
89. Kumagai AK, Eisenberg JB, Pardridge WM: Absorptive-mediated
endocytosis of cationized albumin and a beta-endorphin-cationized
albumin chimeric peptide by isolated brain capillaries. Model system of
blood-brain barrier transport. J Biol Chem 1987, 262(31):15214–15219.
90. Deguchi Y, Naito T, Yuge T, Furukawa A, Yamada S, Pardridge WM, Kimura
R: Blood-brain barrier transport of 125I-labeled basic fibroblast growth
factor. Pharm Res 2000, 17(1):63–69.
91. Triguero D, Buciak J, Pardridge WM: Capillary depletion method for
quantification of blood-brain barrier transport of circulating peptides
and plasma proteins. J Neurochem 1990, 54(6):1882–1888.
92. Connor JR, Menzies SL, St Martin SM, Mufson EJ: A histochemical study of
iron, transferrin, and ferritin in Alzheimer’s diseased brains. J Neurosci Res
1992, 31(1):75–83.
93. Goodman L: Alzheimer’s disease: a clinico-pathologic analysis of twenty-
three cases with a theory on pathogenesis. J Nerv Ment Dis 1953,
118(2):97–130.
94. Falangola MF, Lee SP, Nixon RA, Duff K, Helpern JA: Histological co-
localization of iron in Abeta plaques of PS/APP transgenic mice.
Neurochem Res 2005, 30(2):201–205.
95. Good PF, Perl DP, Bierer LM, Schmeidler J: Selective accumulation of
aluminum and iron in the neurofibrillary tangles of Alzheimer’s disease:
a laser microprobe (LAMMA) study. Ann Neurol 1992, 31(3):286–292.
96. Lovell MA, Robertson JD, Teesdale WJ, Campbell JL, Markesbery WR:
Copper, iron and zinc in Alzheimer’s disease senile plaques. J Neurol Sci
1998, 158(1):47–52.
97. Bush AI: The metal theory of Alzheimer’s disease. J Alzheimers Dis 2013,
33(Suppl 1):S277–S281.
98. Connor JR, Snyder BS, Beard JL, Fine RE, Mufson EJ: Regional distribution of
iron and iron-regulatory proteins in the brain in aging and Alzheimer’s
disease. J Neurosci Res 1992, 31(2):327–335.
99. Loeffler D, Connor J, Juneau P, Snyder B, Kanaley L, DeMaggio A, Nguyen H,
Brickman C, LeWitt P: Transferrin and iron in normal, Alzheimer’s disease,
and Parkinson’s disease brain regions. J Neurochem 1995, 65(2):710–716.
100. Yu X, Du T, Song N, He Q, Shen Y, Jiang H, Xie J: Decreased iron levels in
the temporal cortex in postmortem human brains with Parkinson
disease. Neurology 2013, 80(5):492–495.
101. Grundke-Iqbal I, Fleming J, Tung Y-C, Lassmann H, Iqbal K, Joshi J: Ferritin is
a component of the neuritic (senile) plaque in Alzheimer dementia.
Acta neuropathologica 1990, 81(2):105–110.102. Jellinger K, Paulus W, Grundke-Iqbal I, Riederer P, Youdim MB: Brain iron
and ferritin in Parkinson’s and Alzheimer’s diseases. J Neural Transm Park
Dis Dement Sect 1990, 2(4):327–340.
103. Li X, Liu Y, Zheng Q, Yao G, Cheng P, Bu G, Xu H, Zhang YW: Ferritin light
chain interacts with PEN-2 and affects gamma-secretase activity.
Neurosci Lett 2013, 548:90–94.
104. Connor JR, Boeshore KL, Benkovic SA, Menzies SL: Isoforms of ferritin
have a specific cellular distribution in the brain. J Neurosci Res 1994,
37(4):461–465.
105. Winkler EA, Bell RD, Zlokovic BV: Central nervous system pericytes in
health and disease. Nat Neurosci 2011, 14(11):1398–1405.
106. Merlini M, Meyer EP, Ulmann-Schuler A, Nitsch RM: Vascular beta-amyloid
and early astrocyte alterations impair cerebrovascular function and
cerebral metabolism in transgenic arcAbeta mice. Acta Neuropathol 2011,
122(3):293–311.
107. Morris CM, Kerwin JM, Edwardson JA: Non-haem iron histochemistry of
the normal and Alzheimer’s disease hippocampus. Neurodegeneration
1994, 3(4):267–275.
doi:10.1186/2051-5960-1-55
Cite this article as: Raha et al.: The systemic iron-regulatory proteins
hepcidin and ferroportin are reduced in the brain in Alzheimer’s
disease. Acta Neuropathologica Communications 2013 1:55.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
